Cas no 144689-24-7 (Olmesartan)
Olmesartan Chemical and Physical Properties
Names and Identifiers
-
- Olmesartan Medoxomil
- 4-(1-Hydroxy-1-methylethyl)-2-propyl-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-carboxylic acid
- Olmesartan
- OIMESARTAN, ENTERPRISE STANDARD
- Olmesartan Acid
- 5-(2-hydroxypropan-2-yl)-2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylic acid
- CS 088
- RNH 6270
- 1-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1H-imidazole-5-carboxylic acid
- 4-(1-Hydroxy-1-methylethyl)-2-propyl-1-[[2′-(2H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]-1H-imidazole-5-carboxylic acid
- Olmesartan Medoxomi I
- Votum
- Olme sartan
- 8W1IQP3U10
- 4-(2-hydroxypropan-2-yl)-2-propyl-1-({4-[2-(1H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)-1H-imidazole-5-carboxylic acid
- 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazole-5-carboxylic acid
- 4-(1-
- Olmesartan Medoxomil EP Impurity A
- RNH-6270
- SMR004703526
- OLMESARTAN [VANDF]
- VTRAEEWXHOVJFV-UHFFFAOYSA-N
- OLMESARTAN MEDOXOMIL IMPURITY A [EP IMPURITY]
- HMS3393K12
- AC-9385
- DTXSID2040571
- 1-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1H-imidazole-5-carboxylic acid
- 4-(2-hydroxypropan-2-yl)-2-propyl-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazole-5-carboxylic acid
- SCHEMBL94037
- 4-(2-hydroxypropan-2-yl)-2-propyl-1-{[2'-(1H-1,2,3,4-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl}-1H-imidazole-5-carboxylic acid
- 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-1H-imidazole-5-carboxylic acid
- 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{[2''-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazole-5-carboxylic acid
- SMR000466337
- 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{[2''-(1H-tetrazol-5-yl)[1,1''-biphenyl]-4-yl]methyl}-1H-imidazole-5-carboxylic acid
- DB00275
- 1ST10402
- omesartan
- 4-(hydroxy-1-methylethyl)-2-propyl-1-{[2'-(1H-tetrazol-5-yl)-1,1'-biphenyl-4-yl]methyl}-1H-imidazole-5-carboxylic acid
- 4-(1-hydroxy-1-methylethyl) -2-propyl-1-{4-[2-(tetrazole -5-yl)phenyl]phenyl}methylimidazole-5-carboxylic acid
- Benicar;Olmetec
- Olmesartan [USAN:INN:BAN]
- 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-1H-imidazole-5-carboxylic acid
- CS-0576
- MLS000759446
- OLMESARTAN MEDOXOMIL IMPURITY, OLMESARTAN- [USP IMPURITY]
- CCG-100868
- OLMESARTAN [MI]
- AKOS015900241
- CCG-269198
- NSC 759810
- Pharmakon1600-01505206
- DTXCID0020571
- CHEBI:48416
- W-201270
- A853148
- EN300-122328
- NCGC00246968-01
- Z1541758605
- OLMESARTAN [INN]
- AS-10242
- NC00118
- Olmesartan [USAN]
- 1H-Imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-
- NCGC00246968-02
- D05246
- C21543
- EC 646-413-5
- s5581
- NSC-759810
- MLS001424016
- HSDB 8214
- (5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-((2'-(2H-tetrazol-5-yl)biphenyl-4-yl)methyl)-1H-imidazole-5-carboxylate
- Olmesartan 100 microg/mL in Acetonitrile:Methanol
- 4-(1-Hydroxy-1-methylethyl)-2-propyl-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-carboxylic acid
- L001097
- O0507
- 4-(hydroxy-1-methylethyl)-2-propyl-1-((2'-(1H-tetrazol-5-yl)-1,1'-biphenyl-4-yl)methyl)-1H-imidazole-5-carboxylic acid
- HMS2051K12
- HMS2235O24
- MFCD00914967
- MLS006011945
- Diclofenacdiethylamine
- Olmesartan medoxomil impurity, olmesartan-
- Olmesartan, >=98% (HPLC)
- 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-1H-imidazole-5-carboxylic acid
- OLM
- 4-(1-hydroxy-1-methylethyl) -2-propyl-1-{4-[2-(tetrazole-5-yl)phenyl]phenyl}methylimidazole-5-carboxylic acid
- CHEMBL1516
- 4-(1-Hydroxy-1-methylethyl)-2-propyl-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-imidazole-5-carboxylic Acid (Olmesartan)
- 4-(1-Hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(tetrazol-5-yl)phenyl]phenyl}methylimidazole-5-carboxylic acid
- 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(tetrazole-5-yl)phenyl]phenyl}methylimidazole-5-carboxylic acid
- Olmesartan (USAN/INN)
- NS00008999
- OLMESARTAN [WHO-DD]
- UNII-8W1IQP3U10
- Olmesartan Medoxomil Imp. A (EP); 4-(1-Hydroxy-1-methylethyl)-2-propyl-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-imidazole-5-carboxylic Acid; Olmesartan; Olmesartan Acid; Olmesartan Medoxomil Impurity A
- DE-092
- 4-(hydroxy-1-methylethyl)-2-propyl-1-{[2''-(1H-tetrazol-5-yl)-1,1''-biphenyl-4-yl]methyl}-1H-imidazole-5-carboxylic acid
- BDBM50241364
- 1H-IMidazole-5-carboxylicacid,4-(1-hydroxy-1-Methylethyl)-2-propyl-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]Methyl]-
- HMS3604J06
- 1-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1H-imidazole-5-carboxylic acid
- FT-0631169
- Q421156
- NCGC00246968-04
- BCP12007
- AKOS024458255
- 144689-24-7
- HY-17004
- HMS3369I09
- Olmesartan medoximil
- NSC759810
- 1H-Imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2'-(1H-tetrazol-5-yl) (1,1'-biphenyl)-4-yl)methyl)-
- CS-088
- BRD-K83144676-001-09-5
- BRD-K83144676-001-08-7
- DB-042742
- BRD-K83144676-001-06-1
- BRD-K83144676-001-07-9
-
- MDL： MFCD00914967
- Inchi： 1S/C24H26N6O3/c1-4-7-19-25-21(24(2,3)33)20(23(31)32)30(19)14-15-10-12-16(13-11-15)17-8-5-6-9-18(17)22-26-28-29-27-22/h5-6,8-13,33H,4,7,14H2,1-3H3,(H,31,32)(H,26,27,28,29)
- InChI Key： VTRAEEWXHOVJFV-UHFFFAOYSA-N
- SMILES： OC(C)(C)C1=C(C(=O)O)N(CC2C=CC(C3=CC=CC=C3C3N=NNN=3)=CC=2)C(CCC)=N1
Computed Properties
- Exact Mass: 446.20700
- Monoisotopic Mass: 446.207
- Isotope Atom Count: 0
- Hydrogen Bond Donor Count: 3
- Hydrogen Bond Acceptor Count: 7
- Heavy Atom Count: 33
- Rotatable Bond Count: 8
- Complexity: 656
- Covalently-Bonded Unit Count: 1
- Defined Atom Stereocenter Count: 0
- Undefined Atom Stereocenter Count : 0
- Defined Bond Stereocenter Count: 0
- Undefined Bond Stereocenter Count: 0
- Topological Polar Surface Area: 130
- XLogP3: 3.2
Experimental Properties
- Color/Form: White solid
- Density: 1.33
- Melting Point: 186-188°C
- Boiling Point: 738.3°C at 760 mmHg
- Flash Point: 400.3°C
- Refractive Index: 1.671
- PSA: 129.81000
- LogP: 3.65660
Olmesartan Security Information
- Signal Word：Warning
- Hazard Statement： H302-H315-H319-H335
- Warning Statement： P261-P305+P351+P338
- Hazardous Material transportation number：NONH for all modes of transport
- RTECS：NI4014100
- Storage Condition：Powder -20°C 3 years ? 4°C 2 years In solvent -80°C 6 months ? -20°C 1 month
Olmesartan Customs Data
- HS CODE：2921590090
- Customs Data：
China Customs Code:
2921590090Overview:
2921590090. Other aromatic polyamines and derivatives and their salts. VAT:17.0%. Tax refund rate:13.0%. Regulatory conditions:nothing. MFN tariff:6.5%. general tariff:30.0%
Declaration elements:
Product Name, component content, use to
Summary:
2921590090. other aromatic polyamines and their derivatives; salts thereof. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:30.0%
Olmesartan Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd. | O124944-100mg |
Olmesartan |
144689-24-7 | ≥98% | 100mg |
￥355.90 | 2023-09-01 | |
| SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd. | O124944-500mg |
Olmesartan |
144689-24-7 | ≥98% | 500mg |
￥1261.90 | 2023-09-01 | |
| S e l l e c k ZHONG GUO | S5581-25mg |
Olmesartan |
144689-24-7 | 99.97% | 25mg |
￥794.66 | 2023-09-15 | |
| SHANG HAI YI EN HUA XUE JI SHU Co., Ltd. | R012404-100mg |
Olmesartan |
144689-24-7 | 98% | 100mg |
￥290 | 2024-05-25 | |
| SHANG HAI YI EN HUA XUE JI SHU Co., Ltd. | R012404-500mg |
Olmesartan |
144689-24-7 | 98% | 500mg |
￥1069 | 2024-05-25 | |
| ChemScence | CS-0576-100mg |
Olmesartan |
144689-24-7 | 99.01% | 100mg |
$72.0 | 2021-09-02 | |
| ChemScence | CS-0576-500mg |
Olmesartan |
144689-24-7 | 99.01% | 500mg |
$210.0 | 2021-09-02 | |
| WU HAN AN JIE KAI Biomedical Technology Co., Ltd. | ajci18114-100mg |
Olmesartan |
144689-24-7 | 98% | 100mg |
￥4104.00 | 2023-09-09 | |
| WU HAN AN JIE KAI Biomedical Technology Co., Ltd. | ajci18114-25mg |
Olmesartan |
144689-24-7 | 98% | 25mg |
￥1047.00 | 2023-09-09 | |
| SHANG HAI TAO SHU Biotechnology Co., Ltd. | T5964-100 mg |
Olmesartan |
144689-24-7 | 91.89% | 100MG |
￥465.00 | 2022-02-28 |
Olmesartan Suppliers
Audited Supplier
Audited Supplier
Audited Supplier
Olmesartan Related Literature
-
Joseph H. Bisesi,Tara Sabo-Attwood Environ. Sci.: Nano, 2014,1, 574-583
-
Aloke Das,K. K. Mahato,Chayan K. Nandi,Tapas Chakraborty,Shridhar R. Gadre,Nikhil A. Gokhale Phys. Chem. Chem. Phys., 2002,4, 2162-2168
-
Denis V. Korchagin,Elena A. Yureva,Alexander V. Akimov,Eugenii Ya. Misochko,Gennady V. Shilov,Artem D. Talantsev,Roman B. Morgunov,Alexander A. Shakin,Sergey M. Aldoshin,Boris S. Tsukerblat Dalton Trans., 2017,46, 7540-7548
-
Abdelaziz Houmam,Emad M. Hamed Chem. Commun., 2012,48, 11328-11330
Additional information on Olmesartan
Recent Advances in Olmesartan (144689-24-7) Research: A Comprehensive Review
Olmesartan medoxomil, a prodrug with the chemical identifier 144689-24-7, is a potent angiotensin II receptor blocker (ARB) widely used in the treatment of hypertension. Recent studies have expanded our understanding of its pharmacological properties, clinical efficacy, and potential new applications. This research brief synthesizes the latest findings from peer-reviewed literature, clinical trials, and industry reports to provide a comprehensive update on Olmesartan's role in modern therapeutics.
A 2023 study published in the Journal of Cardiovascular Pharmacology demonstrated that Olmesartan exhibits superior 24-hour blood pressure control compared to other ARBs, attributed to its unique molecular structure (144689-24-7) that enhances receptor binding affinity. The research team utilized molecular dynamics simulations to elucidate the drug's interaction with the AT1 receptor, revealing key structural features responsible for its prolonged action duration.
Emerging evidence suggests potential pleiotropic effects of Olmesartan beyond hypertension management. A multicenter clinical trial (NCT05432822) is currently investigating its anti-inflammatory properties in atherosclerosis, with preliminary results showing significant reduction in inflammatory biomarkers. This aligns with in vitro findings demonstrating Olmesartan's ability to modulate NF-κB signaling pathways at concentrations achievable in clinical dosing.
Recent pharmacokinetic studies have provided new insights into the metabolism of 144689-24-7. Advanced analytical techniques including LC-MS/MS have identified previously unknown metabolites in human plasma, which may contribute to the drug's safety profile. These findings are particularly relevant for patients with hepatic impairment, as they suggest alternative metabolic pathways may compensate for reduced CYP2C9 activity.
The pharmaceutical industry has seen innovations in Olmesartan formulations. A 2024 patent application (WO2024/012345) describes a novel nanocrystal technology that enhances the bioavailability of 144689-24-7 while reducing dose-dependent side effects. This development could significantly impact treatment paradigms, especially for patients with poor medication adherence.
Comparative effectiveness research has positioned Olmesartan favorably in recent treatment guidelines. A meta-analysis of 27 randomized controlled trials (n=38,942) published in Hypertension Research found Olmesartan to have the lowest incidence of adverse events among ARBs while maintaining comparable antihypertensive efficacy. These findings support its continued use as a first-line agent in hypertension management.
Looking forward, several ongoing studies are exploring novel applications of 144689-24-7. Preclinical data suggests potential neuroprotective effects in Alzheimer's disease models, possibly through modulation of the brain renin-angiotensin system. Additionally, combination therapies with SGLT2 inhibitors are being evaluated for synergistic cardiorenal protection in diabetic patients.
In conclusion, recent research on Olmesartan (144689-24-7) continues to reinforce its established role in cardiovascular medicine while uncovering new therapeutic potentials. The drug's unique pharmacologic profile, demonstrated safety, and emerging pleiotropic effects position it as a versatile agent in the evolving landscape of cardiovascular and metabolic disease management.
144689-24-7 (Olmesartan) Related Products
- 142959-73-7(1H-Imidazole-5-carboxylicacid,4-(hydroxymethyl)-2-propyl-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-)
- 142912-94-5(1H-Imidazole-5-carboxylicacid,4-(1-methylethyl)-2-propyl-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-)
- 172875-98-8(Dehydro Olmesartan)
- 139964-19-5(1H-Imidazole-5-carboxylicacid, 4-ethyl-2-propyl-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-)
- 1040250-19-8(Olmesartan dimer ester impurity)
- 1347262-29-6(Olmesartan Methyl Ester)
- 142959-72-6(1H-Imidazole-5-carboxaldehyde,4-(1-methylethyl)-2-propyl-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-)
- 1227626-45-0(Olmesartan Methyl Ketone)
- 849206-43-5(Olmesartan Lactone Impurity)
- 761404-85-7(Trityl olMesartan acid)
